Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

NCT04826679 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab, nab-paclitaxel, cisplatin

Sponsor

Sun Yat-sen University

Collaborators

[object Object]